NASDAQ:OPNT Opiant Pharmaceuticals - OPNT Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Opiant Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Add Compare Share Share Today's Range N/A50-Day Range$20.03▼$21.1052-Week Range N/AVolume562,700 shsAverage Volume77,920 shsMarket Capitalization$108.83 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesShort InterestSocial Media About Opiant Pharmaceuticals (NASDAQ:OPNT) StockOpiant Pharmaceuticals, Inc. is a pharmaceutical company, which engages in the development of pharmaceutical solutions for common addictions and related disorders. The firm focuses on developing treatment to reverse opioid overdoses, treatment for overweight and obese patients with binge eating disorder and treatment for patients with Bulimia Nervosa. Its principal product Naloxone is a medicine which is available through injection can reverse the overdose of prescription and illicit opioids. The company was founded on June 21, 2005 and is headquartered in Santa Monica, CA.Read More Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Stock News HeadlinesMarch 3, 2023 | msn.comIndivior Acquires Opiant Pharmaceuticals Strengthening Its Addiction Treatment And Science PortfolioFebruary 22, 2023 | finance.yahoo.comOpiant Pharmaceuticals, Inc.'s (NASDAQ:OPNT) largest shareholders are individual investors with 52% ownership, institutions own 33%March 24, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. February 7, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces CFIUS Approval for Proposed Acquisition by Indivior PLCJanuary 26, 2023 | seekingalpha.comHorizon Pharma, Opiant fall amid Elizabeth Warren concern about pharma deals (update)January 19, 2023 | finance.yahoo.comOpiant Pharmaceuticals Announces FDA Acceptance and Priority Review of NDA for OPNT003, Nasal Nalmefene, for Opioid OverdoseJanuary 13, 2023 | seekingalpha.comOpiant Pharmaceuticals: Nano-Cap Buyout With Interesting CVR Thrown InJanuary 7, 2023 | businesswire.comOPIANT PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Opiant ...March 24, 2023 | Stansberry Research (Ad)The gold catalyst we’ve waited forIf you thought the SVB meltdown was bad… watch out. Because even bigger red flag just appeared. This signal proves that a recession is likely right around the corner. It will take most by surprise. Stocks will crash. Millions will go jobless, and lose their homes. But there is ONE important step you should take today to make sure you come out the other side OK. November 22, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Rolling NDA Submission for OPNT003, Nasal Nalmefene, for Opioid OverdoseNovember 15, 2022 | benzinga.comOPNT Alert: Monsey Firm of Wohl & Fruchter LLP Investigating Sale of Opiant PharmaceuticalsNovember 15, 2022 | benzinga.comEQUITY ALERT: The M&A Class Action Firm Announces the Investigation of Opiant Pharmaceuticals, Inc. - OPNTNovember 14, 2022 | benzinga.comShareholder Alert: Ademi LLP investigates whether Opiant Pharmaceuticals Inc. has obtained a Fair Price in its transaction with IndiviorNovember 14, 2022 | benzinga.comOPNT Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Opiant Pharmaceuticals, Inc. Is Fair to ShareholdersNovember 14, 2022 | nasdaq.comIndivior To Buy Opiant For $145 Mln In CashNovember 14, 2022 | seekingalpha.comOpiant surges 123% as Indivior set to acquire overdose therapy maker for $145MNovember 14, 2022 | marketwatch.comOpiant Pharmaceuticals Shares Surge Premarket on Takeover by Indivior >OPNTNovember 14, 2022 | finance.yahoo.comIndivior PLC to Acquire Opiant PharmaceuticalsNovember 14, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Third Quarter 2022 Financial ResultsNovember 14, 2022 | finance.yahoo.comNarcan Owner Opiant to Be Acquired by Indivior for $145 MillionNovember 2, 2022 | finance.yahoo.comThe past five years for Opiant Pharmaceuticals (NASDAQ:OPNT) investors has not been profitableOctober 27, 2022 | finance.yahoo.comOpiant Pharmaceuticals to Report Third Quarter 2022 Financial Results and Host Conference Call and Webcast on November 14, 2022October 6, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Completion of Enrollment in Phase 2 Clinical Trial of OPNT002, Nasal Naltrexone, in Patients with Alcohol Use DisorderOctober 5, 2022 | marketwatch.comINVESTIGATION ALERT: Fields Kupka & Shukurov LLP Is Investigating Opiant Pharmaceuticals, Inc. for Potential Breach of Fiduciary Duty ClaimsAugust 22, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Notice of Allowance for U.S. Patent with Claims Covering OPNT004 for the Treatment of Cannabinoid Hyperemesis SyndromeAugust 13, 2022 | finance.yahoo.comAnalysts Just Shaved Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts DramaticallyAugust 11, 2022 | finance.yahoo.comOpiant Pharmaceuticals Announces Second Quarter and First Half 2022 Financial Results and Provides Corporate UpdateSee More Headlines Receive OPNT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Opiant Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address OPNT Company Calendar Last Earnings11/11/2021Today3/24/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:OPNT CUSIPN/A CIK1108924 Webwww.opiant.com Phone(310) 598-5410Fax917-322-2105Employees37Year Founded2009Profitability EPS (Most Recent Fiscal Year)($6.56) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$3.01 million Net Margins-147.90% Pretax Margin-147.84% Return on Equity-97.03% Return on Assets-59.66% Debt Debt-to-Equity Ratio0.60 Current Ratio5.48 Quick Ratio5.48 Sales & Book Value Annual Sales$47.78 million Price / Sales0.00 Cash FlowN/A Price / Cash Flow24.75 Book Value$9.92 per share Price / BookN/AMiscellaneous Outstanding Shares5,270,000Free Float3,865,000Market Cap$108.83 million OptionableNot Optionable Beta0.84 Social Links Key ExecutivesRoger CrystalPresident, Chief Executive Officer & DirectorDavid D. O'TooleChief Financial Officer & SecretaryPhil SkolnickChief Scientific OfficerMark Jason H. EllisonChief Development OfficerMatthew R. RuthChief Commercial OfficerKey CompetitorsPuma BiotechnologyNASDAQ:PBYIViveon Health AcquisitionNYSE:VHAQRVL PharmaceuticalsNASDAQ:RVLPTrevi TherapeuticsNASDAQ:TRVICapricor TherapeuticsNASDAQ:CAPRView All CompetitorsInsiders & InstitutionsMorgan StanleyBought 190,441 shares on 2/15/2023Ownership: 3.830%Schonfeld Strategic Advisors LLCBought 42,300 shares on 2/15/2023Ownership: 0.820%Fifth Lane Capital LPBought 15,000 shares on 2/15/2023Ownership: 0.291%Mariner LLCSold 3,000 shares on 2/15/2023Ownership: 0.204%Gamco Investors INC. ET ALBought 10,000 shares on 2/15/2023Ownership: 0.194%View All Insider TransactionsView All Institutional Transactions OPNT Stock - Frequently Asked Questions Should I buy or sell Opiant Pharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 2 hold ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" OPNT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OPNT, but not buy additional shares or sell existing shares. View OPNT analyst ratings or view top-rated stocks. How were Opiant Pharmaceuticals' earnings last quarter? Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) posted its quarterly earnings results on Thursday, November, 11th. The technology company reported $0.56 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.15 by $0.41. The technology company earned $16.34 million during the quarter, compared to analysts' expectations of $12.45 million. Opiant Pharmaceuticals had a negative trailing twelve-month return on equity of 97.03% and a negative net margin of 147.90%. During the same quarter in the prior year, the company posted $0.15 EPS. What other stocks do shareholders of Opiant Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include Cara Therapeutics (CARA), AcelRx Pharmaceuticals (ACRX), Sangamo Therapeutics (SGMO), Synchrony Financial (SYF), Vodafone Group Public (VOD), Agenus (AGEN), Aldeyra Therapeutics (ALDX), Aurinia Pharmaceuticals (AUPH), Corbus Pharmaceuticals (CRBP) and CyberArk Software (CYBR). What is Opiant Pharmaceuticals' stock symbol? Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT." Who are Opiant Pharmaceuticals' major shareholders? Opiant Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Western Standard LLC (8.22%), Morgan Stanley (3.83%), Renaissance Technologies LLC (2.84%), Wells Fargo & Company MN (2.65%), Dimensional Fund Advisors LP (1.94%) and New York Life Investment Management LLC (1.20%). Insiders that own company stock include Brian Gorman, Craig A Collard, Craig A Collard, David D O'toole, Gabrielle Alison Silver, Mark Jason Heath Ellison, Matthew R Ruth, Michael Sinclair, Phil Skolnick, Roger Crystal and Thomas T Thomas. View institutional ownership trends. How do I buy shares of Opiant Pharmaceuticals? Shares of OPNT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. How much money does Opiant Pharmaceuticals make? Opiant Pharmaceuticals (NASDAQ:OPNT) has a market capitalization of $0.00 and generates $47.78 million in revenue each year. The technology company earns $3.01 million in net income (profit) each year or ($6.56) on an earnings per share basis. How can I contact Opiant Pharmaceuticals? Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The official website for the company is www.opiant.com. The technology company can be reached via phone at (310) 598-5410, via email at investor.relations@opiant.com, or via fax at 917-322-2105. This page (NASDAQ:OPNT) was last updated on 3/24/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.